S-2531-119
Committee on Health, Education, Labor, and Pensions. Hearings held.
Sponsored by Angela Alsobrooks (D-MD)
What it does
This bill would authorize the Secretary of Health and Human Services (HHS) to award grants to states for programs that increase early detection of and intervention for uterine fibroids, including funding for screening procedures, patient navigation services, and public awareness campaigns. It would also direct HHS to conduct or support research on early detection strategies and to award additional grants for research into pain management disparities in fibroid surgical treatment and related intrauterine conditions such as Asherman's Syndrome. HHS would be required to report findings to Congress every two years.
Who benefits
Women with uterine fibroids — estimated to affect up to 26 million American women between ages 15 and 50, with Black women disproportionately affected in both prevalence and severity. Patients who currently lack access to early screening would benefit from expanded detection programs. State health agencies would receive new federal funding. Patient navigators and gynecological imaging providers would see increased demand for their services. Researchers and academic medical centers studying fibroid treatment disparities and intrauterine conditions would gain access to new grant funding.
Who is hurt
No group faces direct regulatory burden or cost under this bill. Federal taxpayers would bear the cost of any appropriated grant funds, though no specific dollar amount is authorized in the bill text. States that do not apply for or receive grants would not benefit, potentially widening geographic disparities in access. Private insurers are not directly regulated, so patients without coverage for screening procedures may remain underserved even in states that receive grants.
Supporters argue
Supporters argue that uterine fibroids affect up to 80% of women by age 50 and are the leading cause of hysterectomy in the United States, yet remain chronically underfunded in federal research relative to their disease burden. They contend that early detection reduces the need for invasive surgical treatment and that Black women — who are two to three times more likely to develop fibroids and experience more severe symptoms — face documented disparities in pain management during treatment, making targeted federal action both a public health and health equity priority.
Opponents argue
Opponents argue that the bill authorizes grants without specifying a funding amount, leaving its real-world impact entirely dependent on future appropriations that may never materialize, making it largely symbolic. They contend that existing NIH and HHS programs already fund women's health research and that creating a new parallel grant structure adds administrative overhead without guaranteeing better outcomes than directing resources through established channels. Critics may also note that the bill does not address insurance coverage gaps, meaning screening access could remain uneven even in states that participate.
Constitutional context
Congress has broad authority to appropriate funds for public health programs under the Taxing and Spending Clause (Art. I, §8, cl. 1) and to attach conditions to grants to states. NFIB v. Sebelius (2012) affirmed this spending power while noting that grant conditions cannot be so coercive as to leave states no genuine choice; because participation in this grant program is entirely voluntary, no coercion concern arises here.
Checks and balances
The Executive Branch (HHS Secretary) gains discretionary authority to award grants and formulate research strategies; Congress retains oversight through mandatory biennial reports and controls the actual funding level through the appropriations process.
Historical precedent
The Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2005 similarly directed NIH to expand fibroid research and public education, establishing a direct federal precedent for this type of targeted women's health grant legislation.